The sensitivity of exome sequencing in identifying pathogenic mutations for LGMD in the United States

Hemakumar M Reddy, Kyung-Ah Cho, Monkol Lek, Elicia Estrella, Elise Valkanas, Michael D Jones, Satomi Mitsuhashi, Basil T Darras, Anthony A Amato, Hart Gw Lidov, Catherine A Brownstein, David M Margulies, Timothy W Yu, Mustafa A Salih, Louis M Kunkel, Daniel G MacArthur, Peter B Kang, Hemakumar M Reddy, Kyung-Ah Cho, Monkol Lek, Elicia Estrella, Elise Valkanas, Michael D Jones, Satomi Mitsuhashi, Basil T Darras, Anthony A Amato, Hart Gw Lidov, Catherine A Brownstein, David M Margulies, Timothy W Yu, Mustafa A Salih, Louis M Kunkel, Daniel G MacArthur, Peter B Kang

Abstract

The current study characterizes a cohort of limb-girdle muscular dystrophy (LGMD) in the United States using whole-exome sequencing. Fifty-five families affected by LGMD were recruited using an institutionally approved protocol. Exome sequencing was performed on probands and selected parental samples. Pathogenic mutations and cosegregation patterns were confirmed by Sanger sequencing. Twenty-two families (40%) had novel and previously reported pathogenic mutations, primarily in LGMD genes, and also in genes for Duchenne muscular dystrophy, facioscapulohumeral muscular dystrophy, congenital myopathy, myofibrillar myopathy, inclusion body myopathy and Pompe disease. One family was diagnosed via clinical testing. Dominant mutations were identified in COL6A1, COL6A3, FLNC, LMNA, RYR1, SMCHD1 and VCP, recessive mutations in ANO5, CAPN3, GAA, LAMA2, SGCA and SGCG, and X-linked mutations in DMD. A previously reported variant in DMD was confirmed to be benign. Exome sequencing is a powerful diagnostic tool for LGMD. Despite careful phenotypic screening, pathogenic mutations were found in other muscle disease genes, largely accounting for the increased sensitivity of exome sequencing. Our experience suggests that broad sequencing panels are useful for these analyses because of the phenotypic overlap of many neuromuscular conditions. The confirmation of a benign DMD variant illustrates the potential of exome sequencing to help determine pathogenicity.

Conflict of interest statement

Disclosure TWY and LMK have received personal compensation from Claritas Genomics.

Figures

Figure 1
Figure 1
Flow chart of analytic process for the cohort of families with LGMD (top), along with a breakdown of genetic diagnoses by category (bottom).

References

    1. Mitsuhashi S, Kang PB. Update on the genetics of limb girdle muscular dystrophy. Seminars in pediatric neurology. 2012;19:211–218.
    1. Nigro V, Savarese M. Genetic basis of limb-girdle muscular dystrophies: the 2014 update. Acta myologica : myopathies and cardiomyopathies : official journal of the Mediterranean Society of Myology / edited by the Gaetano Conte Academy for the study of striated muscle diseases. 2014;33:1–12.
    1. Moore SA, Shilling CJ, Westra S, Wall C, Wicklund MP, Stolle C, et al. Limb-girdle muscular dystrophy in the United States. Journal of neuropathology and experimental neurology. 2006;65:995–1003.
    1. Yang Y, Muzny DM, Xia F, Niu Z, Person R, Ding Y, et al. Molecular findings among patients referred for clinical whole-exome sequencing. Jama. 2014;312:1870–1879.
    1. Ankala A, da Silva C, Gualandi F, Ferlini A, Bean LJ, Collins C, et al. A comprehensive genomic approach for neuromuscular diseases gives a high diagnostic yield. Annals of neurology. 2015;77:206–214.
    1. Fattahi Z, Kalhor Z, Fadaee M, Vazehan R, Parsimehr E, Abolhassani A, et al. Improved diagnostic yield of neuromuscular disorders applying clinical exome sequencing in patients arising from a consanguineous population. Clin Genet. 2016
    1. Ghaoui R, Cooper ST, Lek M, Jones K, Corbett A, Reddel SW, et al. Use of Whole-Exome Sequencing for Diagnosis of Limb-Girdle Muscular Dystrophy: Outcomes and Lessons Learned. JAMA neurology. 2015:1–9.
    1. Kuhn M, Glaser D, Joshi PR, Zierz S, Wenninger S, Schoser B, et al. Utility of a next-generation sequencing-based gene panel investigation in German patients with genetically unclassified limb-girdle muscular dystrophy. J Neurol. 2016;263:743–750.
    1. Reddy HM, Hamed SA, Lek M, Mitsuhashi S, Estrella E, Jones MD, et al. A homozygous nonsense mutation in SGCA is a common cause of LGMD in Assiut, Egypt. Muscle & nerve. 2016
    1. Mitsuhashi S, Boyden SE, Estrella EA, Jones TI, Rahimov F, Yu TW, et al. Exome sequencing identifies a novel SMCHD1 mutation in facioscapulohumeral muscular dystrophy 2. Neuromuscular disorders : NMD. 2013;23:975–980.
    1. Walters-Sen LC, Hashimoto S, Thrush DL, Reshmi S, Gastier-Foster JM, Astbury C, et al. Variability in pathogenicity prediction programs: impact on clinical diagnostics. Mol Genet Genomic Med. 2015;3:99–110.
    1. Tan D, Yang H, Yuan Y, Bonnemann C, Chang X, Wang S, et al. Phenotype-Genotype Analysis of Chinese Patients with Early-Onset LMNA-Related Muscular Dystrophy. PloS one. 2015;10:e0129699.
    1. Brown CA, Lanning RW, McKinney KQ, Salvino AR, Cherniske E, Crowe CA, et al. Novel and recurrent mutations in lamin A/C in patients with Emery-Dreifuss muscular dystrophy. American journal of medical genetics. 2001;102:359–367.
    1. Giusti B, Lucarini L, Pietroni V, Lucioli S, Bandinelli B, Sabatelli P, et al. Dominant and recessive COL6A1 mutations in Ullrich scleroatonic muscular dystrophy. Annals of neurology. 2005;58:400–410.
    1. Lampe AK, Dunn DM, von Niederhausern AC, Hamil C, Aoyagi A, Laval SH, et al. Automated genomic sequence analysis of the three collagen VI genes: applications to Ullrich congenital muscular dystrophy and Bethlem myopathy. Journal of medical genetics. 2005;42:108–120.
    1. Mercuri E, Lampe A, Allsop J, Knight R, Pane M, Kinali M, et al. Muscle MRI in Ullrich congenital muscular dystrophy and Bethlem myopathy. Neuromuscular disorders : NMD. 2005;15:303–310.
    1. Sato I, Wu S, Ibarra MC, Hayashi YK, Fujita H, Tojo M, et al. Congenital neuromuscular disease with uniform type 1 fiber and RYR1 mutation. Neurology. 2008;70:114–122.
    1. Tilgen N, Zorzato F, Halliger-Keller B, Muntoni F, Sewry C, Palmucci LM, et al. Identification of four novel mutations in the C-terminal membrane spanning domain of the ryanodine receptor 1: association with central core disease and alteration of calcium homeostasis. Human molecular genetics. 2001;10:2879–2887.
    1. Watts GD, Wymer J, Kovach MJ, Mehta SG, Mumm S, Darvish D, et al. Inclusion body myopathy associated with Paget disease of bone and frontotemporal dementia is caused by mutant valosin-containing protein. Nature genetics. 2004;36:377–381.
    1. Richard I, Broux O, Allamand V, Fougerousse F, Chiannilkulchai N, Bourg N, et al. Mutations in the proteolytic enzyme calpain 3 cause limb-girdle muscular dystrophy type 2A. Cell. 1995;81:27–40.
    1. Richard I, Roudaut C, Saenz A, Pogue R, Grimbergen JE, Anderson LV, et al. Calpainopathy-a survey of mutations and polymorphisms. American journal of human genetics. 1999;64:1524–1540.
    1. Bonnemann CG, Wong J, Jones KJ, Lidov HG, Feener CA, Shapiro F, et al. Primary gamma-sarcoglycanopathy (LGMD 2C): broadening of the mutational spectrum guided by the immunohistochemical profile. Neuromuscular disorders : NMD. 2002;12:273–280.
    1. Bolduc V, Marlow G, Boycott KM, Saleki K, Inoue H, Kroon J, et al. Recessive mutations in the putative calcium-activated chloride channel Anoctamin 5 cause proximal LGMD2L and distal MMD3 muscular dystrophies. American journal of human genetics. 2010;86:213–221.
    1. Hicks D, Sarkozy A, Muelas N, Koehler K, Huebner A, Hudson G, et al. A founder mutation in Anoctamin 5 is a major cause of limb-girdle muscular dystrophy. Brain : a journal of neurology. 2011;134:171–182.
    1. Penttila S, Palmio J, Suominen T, Raheem O, Evila A, Muelas Gomez N, et al. Eight new mutations and the expanding phenotype variability in muscular dystrophy caused by ANO5. Neurology. 2012;78:897–903.
    1. Sewry CA, Naom I, D'Alessandro M, Sorokin L, Bruno S, Wilson LA, et al. Variable clinical phenotype in merosin-deficient congenital muscular dystrophy associated with differential immunolabelling of two fragments of the laminin alpha 2 chain. Neuromuscular disorders : NMD. 1997;7:169–175.
    1. Naom I, D'Alessandro M, Sewry CA, Philpot J, Manzur AY, Dubowitz V, et al. Laminin alpha 2-chain gene mutations in two siblings presenting with limb-girdle muscular dystrophy. Neuromuscular disorders : NMD. 1998;8:495–501.
    1. Geranmayeh F, Clement E, Feng LH, Sewry C, Pagan J, Mein R, et al. Genotype-phenotype correlation in a large population of muscular dystrophy patients with LAMA2 mutations. Neuromuscular disorders : NMD. 2010;20:241–250.
    1. Gavassini BF, Carboni N, Nielsen JE, Danielsen ER, Thomsen C, Svenstrup K, et al. Clinical and molecular characterization of limb-girdle muscular dystrophy due to LAMA2 mutations. Muscle & nerve. 2011;44:703–709.
    1. Marques J, Duarte ST, Costa S, Jacinto S, Oliveira J, Oliveira ME, et al. Atypical phenotype in two patients with LAMA2 mutations. Neuromuscular disorders : NMD. 2014;24:419–424.
    1. Lokken N, Born AP, Duno M, Vissing J. LAMA2-related myopathy: Frequency among congenital and limb-girdle muscular dystrophies. Muscle & nerve. 2015;52:547–553.
    1. Nelson I, Stojkovic T, Allamand V, Leturcq F, Bécane HM, Babuty D, et al. Laminin α2 deficiency-related muscular dystrophy mimicking Emery-Dreifuss and collagen VI related diseases. J Neuromuscul Dis. 2015;2:229–240.
    1. Kroos M, Pomponio RJ, van Vliet L, Palmer RE, Phipps M, Van der Helm R, et al. Update of the Pompe disease mutation database with 107 sequence variants and a format for severity rating. Human mutation. 2008;29:E13–26.
    1. Huie ML, Chen AS, Tsujino S, Shanske S, DiMauro S, Engel AG, et al. Aberrant splicing in adult onset glycogen storage disease type II (GSDII): molecular identification of an IVS1 (-13T-->G) mutation in a majority of patients and a novel IVS10 (+1GT-->CT) mutation. Human molecular genetics. 1994;3:2231–2236.
    1. Gurvich OL, Maiti B, Weiss RB, Aggarwal G, Howard MT, Flanigan KM. DMD exon 1 truncating point mutations: amelioration of phenotype by alternative translation initiation in exon 6. Human mutation. 2009;30:633–640.
    1. Flanigan KM, Dunn DM, von Niederhausern A, Howard MT, Mendell J, Connolly A, et al. DMD Trp3X nonsense mutation associated with a founder effect in North American families with mild Becker muscular dystrophy. Neuromuscular disorders : NMD. 2009;19:743–748.
    1. Flanigan KM, Dunn DM, von Niederhausern A, Soltanzadeh P, Gappmaier E, Howard MT, et al. Mutational spectrum of DMD mutations in dystrophinopathy patients: application of modern diagnostic techniques to a large cohort. Human mutation. 2009;30:1657–1666.
    1. Almomani R, van der Stoep N, Bakker E, den Dunnen JT, Breuning MH, Ginjaar IB. Rapid and cost effective detection of small mutations in the DMD gene by high resolution melting curve analysis. Neuromuscular disorders : NMD. 2009;19:383–390.
    1. Lenk U, Hanke R, Speer A. Carrier detection in DMD families with point mutations, using PCR-SSCP and direct sequencing. Neuromuscular disorders : NMD. 1994;4:411–418.
    1. Hofstra RM, Mulder IM, Vossen R, de Koning-Gans PA, Kraak M, Ginjaar IB, et al. DGGE-based whole-gene mutation scanning of the dystrophin gene in Duchenne and Becker muscular dystrophy patients. Human mutation. 2004;23:57–66.
    1. Mahmood OA, Jiang X, Zhang Q. Limb-girdle muscular dystrophy subtypes: First-reported cohort from northeastern China. Neural regeneration research. 2013;8:1907–1918.
    1. Di Fruscio G, Garofalo A, Mutarelli M, Savarese M, Nigro V. Are all the previously reported genetic variants in limb girdle muscular dystrophy genes pathogenic? European journal of human genetics : EJHG. 2016;24:73–77.
    1. Choi M, Scholl UI, Ji W, Liu T, Tikhonova IR, Zumbo P, et al. Genetic diagnosis by whole exome capture and massively parallel DNA sequencing. Proceedings of the National Academy of Sciences of the United States of America. 2009;106:19096–19101.
    1. Cooper DN, Krawczak M, Polychronakos C, Tyler-Smith C, Kehrer-Sawatzki H. Where genotype is not predictive of phenotype: towards an understanding of the molecular basis of reduced penetrance in human inherited disease. Hum Genet. 2013;132:1077–1130.
    1. Muntoni F, Bonne G, Goldfarb LG, Mercuri E, Piercy RJ, Burke M, et al. Disease severity in dominant Emery Dreifuss is increased by mutations in both emerin and desmin proteins. Brain : a journal of neurology. 2006;129:1260–1268.
    1. Lemmers RJ, Tawil R, Petek LM, Balog J, Block GJ, Santen GW, et al. Digenic inheritance of an SMCHD1 mutation and an FSHD-permissive D4Z4 allele causes facioscapulohumeral muscular dystrophy type 2. Nature genetics. 2012;44:1370–1374.

Source: PubMed

スポンサーと協力者

医学的状態

薬物療法

3
購読する